1- Monday Infectious Disease News – 3rd May

1 – COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

• At its meeting of 20 April 2021, EMA’s safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen.
• PRAC also concluded that these events should be listed as very rare side effects of the vaccine.
• All cases occurred in people under 60 years of age within three weeks after vaccination, the majority in women.

Source: EMA

2 – How staying positive on the day of your vaccination might help your level of immunity

• Excited about the prospect of receiving a COVID-19 vaccination soon?
• There’s more than one reason to be cheerful the day you go in to get your shot, researchers say.
• According to studies performed with other vaccines, many factors can affect the immune response your body has in response to a vaccination — and one of those factors may be your mood.
• A positive outlook may enhance how our bodies respond to immunizations, studies say.

Source: CTV News

3 – Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

• To mitigate the effects of COVID-19, a vaccine is urgently needed.
• BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or alum (Algel).
• BBV152 led to tolerable safety outcomes and enhanced immune responses.
• Both Algel-IMDG formulations were selected for phase 2 immunogenicity trials. Further efficacy trials are warranted.

Source: The Lancet

4- The world’s biggest vaccine producer is running out of Covid-19 vaccines, as second wave accelerates

• In India, the world’s biggest vaccine producer, millions of people are waiting for Covid-19 vaccines amid a devastating second wave of infections.
• India typically produces more than 60% of all vaccines sold globally, and is home to the Serum Institute of India (SII), the world’s largest vaccine maker.
• Its vast manufacturing capability is why the country signed on as a major player in COVAX.
• In the face of crisis, the government and SII have shifted focus from supplying vaccines to COVAX to prioritizing their own citizens at home.

Source: CNN

5 – Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study

• Clindamycin is strongly recommended as an adjunctive treatment to β-lactam antibiotics in patients with severe invasive group A β-haemolytic streptococcal (iGAS) infections.
• However, there is little evidence of a benefit in the use of clindamycin in humans, and its role, if any, in treating patients with invasive non-group A/B β-haemolytic streptococcal (iNABS) infections is unclear.
• Real-world data suggest that increased use of adjunctive clindamycin for invasive iGAS infections, but not iNABS infections, could improve outcomes, even in patients without shock or necrotising fasciitis.

Source: The Lancet

6 – Study: COVID much more likely than vaccines to cause blood clots

• COVID-19—the actual disease—poses 8 to 10 times the threat of blood clots in the brain than do coronavirus vaccines, a large, non–peer-reviewed study led by University of Oxford researchers finds.
• The researchers tallied patients diagnosed as having cerebral venous thrombosis (CVT) in the 2 weeks after they received either their COVID-19 diagnosis or their first dose of the Pfizer/BioNTech or Moderna vaccine from Jan 20, 2020, to Mar 25, 2021.
• The researchers then compared those with rates of CVT in an unmatched cohort who had the flu and in the general population over the same period.
• The risk of CVT was 8 to 10 times higher in the 513,284 patients with a COVID-19 diagnosis than in the 489,871 vaccinees and 100 times greater than in the general population.

Source: CIDRAP

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Antimicrobial Resistance E-News (FNN) Daily Emails?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2020 Antimicrobial Resistance E-News (FNN), for daily publication of Daily News

Read & Download FNN Issue 8 of April 2020 FNN News